{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:02:45Z","timestamp":1775318565212,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jns.2024.122979","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T16:08:26Z","timestamp":1711814906000},"page":"122979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease"],"prefix":"10.1016","volume":"459","author":[{"given":"Sara","family":"Korpela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Sundblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Paucar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter","family":"Niemel\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jns.2024.122979_bb0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Group THsDCR","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jns.2024.122979_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.122979_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-170273","article-title":"A critical evaluation of wet biomarkers for Huntington\u2019s disease: current status and ways forward","volume":"7","author":"Silajdzic","year":"2018","journal-title":"J. Huntington\u2019s Disease"},{"issue":"3","key":"10.1016\/j.jns.2024.122979_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","article-title":"Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease","volume":"15","author":"Constantinescu","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.jns.2024.122979_bb0030","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.jns.2024.122979_bb0035","article-title":"Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease","volume":"3","author":"Vinther-Jensen","year":"2016","journal-title":"Neurol.(R) Neuroimmunol. Neuroinflam."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172762","article-title":"Tau or neurofilament light-which is the more suitable biomarker for Huntington\u2019s disease?","volume":"12","author":"Niemela","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jns.2024.122979_bb0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","article-title":"Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease","volume":"17","author":"Constantinescu","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2024.122979_bb0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.jns.2024.122979_bb0055","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/jnnp.2005.084673","article-title":"Selective reduction of amyloid \u03b242 discriminates Alzheimer\u2019s disease from Huntington\u2019s disease: indication for distinct pathological events in amyloid \u03b2 peptide aggregation","volume":"77","author":"Mollenhauer","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0060","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pharmthera.2007.06.006","article-title":"The role of amyloid beta peptide 42 in Alzheimer\u2019s disease","volume":"116","author":"Findeis","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jns.2024.122979_bb0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.122979_bb0070","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.mp.4001473","article-title":"Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer\u2019s disease in patients with mild cognitive impairment","volume":"9","author":"Hampel","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/01.wnl.0000171397.32851.bc","article-title":"Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline","volume":"65","author":"Moonis","year":"2005","journal-title":"Neurology."},{"issue":"16","key":"10.1016\/j.jns.2024.122979_bb0080","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA."},{"issue":"11","key":"10.1016\/j.jns.2024.122979_bb0085","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","article-title":"Beta amyloid in Alzheimer\u2019s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid","volume":"65","author":"Grimmer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2024.122979_bb0090","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/01.WNL.0000063313.57292.00","article-title":"Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury","volume":"60","author":"Franz","year":"2003","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.jns.2024.122979_bb0095","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2024.122979_bb0100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2024.122979_bb0105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neurobiolaging.2004.08.002","article-title":"Mean age of onset in familial Alzheimer\u2019s disease is determined by amyloid beta 42","volume":"26","author":"Duering","year":"2005","journal-title":"Neurobiol. Aging"},{"issue":"7","key":"10.1016\/j.jns.2024.122979_bb0110","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF03401753","article-title":"Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model","volume":"4","author":"Fiala","year":"1998","journal-title":"Mol. Med."},{"issue":"1\u20132","key":"10.1016\/j.jns.2024.122979_bb0115","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0165-5728(98)00226-4","article-title":"A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced","volume":"93","author":"Johnstone","year":"1999","journal-title":"J. Neuroimmunol."},{"issue":"6570","key":"10.1016\/j.jns.2024.122979_bb0120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/380168a0","article-title":"beta-amyloid-mediated vasoactivity and vascular endothelial damage","volume":"380","author":"Thomas","year":"1996","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.jns.2024.122979_bb0125","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1176\/appi.ajp.2017.17040442","article-title":"Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in cognitively Normal older adults","volume":"175","author":"Donovan","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2024.122979_bb0130","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/1352458518791709","article-title":"CSF beta-amyloid predicts prognosis in patients with multiple sclerosis","volume":"25","author":"Pietroboni","year":"2019","journal-title":"Multiple Scleros. (Houndmills, Basingstoke, England)."},{"issue":"3","key":"10.1016\/j.jns.2024.122979_bb0135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/npp.2010.187","article-title":"Cognitive and cortical plasticity deficits correlate with altered amyloid-beta CSF levels in multiple sclerosis","volume":"36","author":"Mori","year":"2011","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"10.1016\/j.jns.2024.122979_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00401-015-1513-1","article-title":"Astrocytes: a central element in neurological diseases","volume":"131","author":"Pekny","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2024.122979_bb0145","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S0197-4580(03)00051-4","article-title":"Neurons, glia, and plasticity in normal brain aging","volume":"24 Suppl 1","author":"Finch","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"7638","key":"10.1016\/j.jns.2024.122979_bb0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ane.12239","article-title":"Assessing tissue damage in multiple sclerosis: a biomarker approach","volume":"130","author":"Burman","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.jns.2024.122979_bb0160","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jns.2024.122979_bb0165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2024.122979_bb0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199111000-00005","article-title":"Decreased neuronal and increased oligodendroglial densities in Huntington\u2019s disease caudate nucleus","volume":"50","author":"Myers","year":"1991","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"15","key":"10.1016\/j.jns.2024.122979_bb0175","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","article-title":"In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington\u2019s disease subjects","volume":"19","author":"Faideau","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.jns.2024.122979_bb0180","first-page":"487","article-title":"Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington\u2019s disease mouse model","volume":"28","author":"Wood","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.jns.2024.122979_bb0185","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nn.3691","article-title":"Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington\u2019s disease model mice","volume":"17","author":"Tong","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2024.122979_bb0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"International Huntington\u2019s disease collaborative G. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"and the P-HDIotHSG. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches","volume":"153B","author":"Langbehn","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0165-0270(94)90011-6","article-title":"A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults","volume":"51","author":"Rosengren","year":"1994","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.jns.2024.122979_bb0205","doi-asserted-by":"crossref","first-page":"9106","DOI":"10.1038\/s41598-020-66154-y","article-title":"Association between cerebrospinal fluid biomarkers and age-related brain changes in patients with Normal pressure hydrocephalus","volume":"10","author":"Taghdiri","year":"2020","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.jns.2024.122979_bb0210","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","article-title":"Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values","volume":"47","author":"Sjogren","year":"2001","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.jns.2024.122979_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233820","article-title":"Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington\u2019s disease","volume":"15","author":"Lowe","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0220","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006288","article-title":"Physiological functions of APP family proteins","volume":"2","author":"Muller","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/mds.28391","article-title":"Proenkephalin decreases in cerebrospinal fluid with symptom progression of Huntington\u2019s disease","volume":"36","author":"Niemela","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.122979_bb0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1750-1326-6-79","article-title":"Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer\u2019s disease?","volume":"6","author":"Li","year":"2011","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2024.122979_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.779890","article-title":"Evaluation of blood glial fibrillary acidic protein as a potential marker in Huntington\u2019s disease","volume":"12","author":"You","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.122979_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fncel.2015.00278","article-title":"Elusive roles for reactive astrocytes in neurodegenerative diseases","volume":"9","author":"Ben Haim","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jns.2024.122979_bb0250","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","article-title":"The role of microglia and astrocytes in Huntington\u2019s disease","volume":"12","author":"Palpagama","year":"2019","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2024.122979_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193492","article-title":"Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington\u2019s disease","volume":"13","author":"Niemela","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jns.2024.122979_bb0260","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:30:23Z","timestamp":1712910623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2400114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":52,"alternative-id":["S0022510X2400114X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122979","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122979"}}